Back to top

Analyst Blog

AVEO Pharmaceuticals, Inc. (AVEO - Snapshot Report) and Astellas Pharma, Inc. (ALPMY) recently announced that the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will review tivozanib on May 2, 2013.

A New Drug Application (NDA) for tivozanib seeking approval for the treatment of patients with advanced renal cell carcinoma (RCC) was submitted in Sep 2012.  The FDA accepted the application in Nov 2012 with a response expected by Jul 28, 2013.

In Feb 2013, final overall survival (OS) results were announced from the phase III TIVO-1(TIvozanib Versus sOrafenib in 1st line advanced RCC) study.

We note that earlier, the companies had presented results showing that the candidate achieved a statistically significant improvement in the primary endpoint of progression-free survival (PFS) compared to Nexavar.

According to Cancer Research UK, advanced RCC is estimated to affect more than 250,000 people globally.

We note that tivozanib is currently in additional programs and studies like BATON and TAURUS. The BATON (Biomarker Assessment of Tivozanib in ONcology) program includes studies assessing tivozanib biomarkers in solid tumors. The TAURUS (TivozAnib Use veRsUs Sutent in advanced RCC: Patient Preference) study is being conducted to demonstrate patient preference of tivozanib compared to Sutent (sunitinib) in the first-line treatment of advanced RCC.

We expect investor focus to remain on the outcome of the FDA advisory panel meeting.

While AVEO carries a Zacks Rank #3 (Hold), Astellas carries a Zacks Rank #4 (Sell). Currently, Lannett Company, Inc. (LCI - Snapshot Report) and SIGA Technologies, Inc. look more attractive with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%